Chinese biotech Alphamab seeks approval for HK IPO of up to $350 mln -sources

Chinese biopharmaceutical company, Alphamab Oncology, plans to seek listing approval early next month for a Hong Kong initial public offering (IPO) of up to $350 million, people with direct knowledge of the matter said.